<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Citalopram - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../sickbay-shared.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Citalopram</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Neuro / Psych</div>
      <h1>Citalopram</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Citalopram 20mg Tablets</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Major depressive disorder (initial therapy)</strong>
            <ul>
              <li>Starting dose: 20 mg PO once daily (typically in AM or PM; consistent timing)</li>
              <li>May increase to 40 mg once daily after minimum 1 week if needed and tolerated</li>
              <li>Maximum dose: 40 mg/day (do NOT exceed due to QT prolongation risk)</li>
            </ul>
          </li>
          <li><strong>Generalized anxiety disorder / panic disorder (off-label but commonly used)</strong>
            <ul>
              <li>Starting dose: 10–20 mg PO once daily</li>
              <li>Titrate as needed to 20–40 mg once daily based on response/tolerability</li>
            </ul>
          </li>
          <li><strong>Special populations</strong>
            <ul>
              <li>Older adults (&gt;60 years): Maximum 20 mg/day (increased QT risk)</li>
              <li>Hepatic impairment: Maximum 20 mg/day</li>
              <li>CYP2C19 poor metabolizers: Maximum 20 mg/day</li>
            </ul>
          </li>
          <li><strong>Discontinuation</strong>
            <ul>
              <li>Taper gradually over several weeks to months when stopping (reduce withdrawal symptoms)</li>
              <li>Do NOT stop abruptly after prolonged use</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Major depressive disorder (approved indication)</li>
          <li>Generalized anxiety disorder (common off-label use)</li>
          <li>Panic disorder (off-label)</li>
          <li>Obsessive-compulsive disorder (off-label; other SSRIs preferred)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to citalopram or escitalopram</li>
          <li>Concurrent use or within 14 days of MAO inhibitors (serotonin syndrome risk; contraindicated)</li>
          <li>Concurrent use with pimozide (QT prolongation; contraindicated)</li>
          <li><strong>Black box warning:</strong> Increased risk of suicidal thinking and behavior in children, adolescents, and young adults (up to age 24) with major depressive disorder and other psychiatric disorders
            <ul>
              <li>Monitor closely for worsening depression, suicidality, or unusual behavior changes, especially during initial months and dose changes</li>
            </ul>
          </li>
          <li>QT prolongation risk: dose-dependent; do NOT exceed 40 mg/day (20 mg/day in high-risk groups)
            <ul>
              <li>Caution with other QT-prolonging drugs, cardiac disease, electrolyte abnormalities</li>
              <li>ECG monitoring recommended in high-risk patients</li>
            </ul>
          </li>
          <li>Serotonin syndrome risk: especially with other serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, linezolid, St. John's wort, etc.)</li>
          <li>Bleeding risk: SSRIs affect platelet function; caution with NSAIDs, ASA, anticoagulants</li>
          <li>Hyponatremia risk (especially older adults; SIADH mechanism)</li>
          <li>Mania/hypomania activation in bipolar disorder</li>
          <li>Pregnancy: weigh risks/benefits; potential neonatal complications, persistent pulmonary hypertension of newborn (PPHN) if used in late pregnancy</li>
          <li>Sexual dysfunction (common; dose-related)</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Nausea, dry mouth, diarrhea, constipation</li>
          <li>Insomnia or somnolence, fatigue</li>
          <li>Sexual dysfunction (decreased libido, delayed ejaculation, anorgasmia; common)</li>
          <li>Sweating, tremor</li>
          <li>Headache, dizziness</li>
          <li>Weight changes (usually gain over time)</li>
          <li>QT prolongation (dose-dependent)</li>
          <li>Hyponatremia (especially older adults)</li>
          <li>Serotonin syndrome (rare but serious; with other serotonergic drugs)</li>
          <li>Discontinuation syndrome if stopped abruptly (dizziness, nausea, headache, irritability, paresthesias)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>Take once daily, same time each day (morning or evening; consistency important)</li>
          <li>May take with or without food</li>
          <li>Full therapeutic effect typically takes 4–6 weeks; counsel patient to continue even if not immediate improvement</li>
          <li>Counsel about suicidality risk (especially young adults); ensure close follow-up during initial weeks</li>
          <li>Counsel about sexual side effects and management strategies (common reason for discontinuation)</li>
          <li>When discontinuing: taper gradually over weeks to months (do NOT stop abruptly)</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Suicidal ideation/behavior, especially during first few months and after dose changes (black box warning)</li>
          <li>Mood, anxiety symptoms, functional improvement (typically reassess at 2–4 weeks, then regularly)</li>
          <li>Activation/agitation, mania symptoms (especially if bipolar disorder possible)</li>
          <li>Serotonin syndrome symptoms if on multiple serotonergic drugs (agitation, confusion, tremor, hyperthermia, hyperreflexia)</li>
          <li>Bleeding events (especially if concurrent antiplatelet/anticoagulant therapy)</li>
          <li>Sodium level if high risk for hyponatremia (older adults, diuretics, SIADH risk factors)</li>
          <li>QT interval if high-risk patient, doses &gt;20 mg, or concurrent QT-prolonging drugs (ECG when feasible)</li>
          <li>Sexual function (ask directly; often underreported)</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>SSRIs like citalopram are generally NOT initiated at sea unless under direct medical supervision/telemedicine guidance (require close monitoring, especially initially)</li>
          <li>If crew member already stabilized on citalopram before deployment: ensure adequate supply, document current dose and duration, and have plan for mental health follow-up/monitoring</li>
          <li>Black box warning for suicidality: critical concern in isolated maritime environment; ensure mental health support and evacuation plan if needed</li>
          <li>Do NOT stop abruptly if supply runs out: taper if possible and arrange resupply/evacuation for psychiatric continuity</li>
          <li>Operational considerations: initial weeks may cause somnolence or insomnia; assess fitness for safety-critical duties</li>
          <li>Document mental health baseline and ongoing status clearly; maintain communication with shore-based mental health provider</li>
          <li>QT prolongation: if ECG available, consider baseline and follow-up monitoring especially if dose &gt;20 mg or cardiac risk factors</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (citalopram tablets): <a href="https://pdf.hres.ca/dpd_pm/00067881.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00067881.PDF</a></li>
          <li>FDA Safety Communication - Citalopram and QT prolongation: <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-high-doses-celexa-citalopram" target="_blank" rel="noopener">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-high-doses-celexa-citalopram</a></li>
          <li>Medscape - Citalopram reference: <a href="https://reference.medscape.com/drug/celexa-citalopram-342957" target="_blank" rel="noopener">https://reference.medscape.com/drug/celexa-citalopram-342957</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
